Gallen Consensus Statements on breast cancer have supported the use of the Ki-67 index (as determined by MIB-1) in deciding whether to offer chemotherapy to patients with hormone positive, node negative cancers, and also as part of the criteria in separating luminal A from luminal B carcinomas23, 24. This evidence concerns the gene MKI67 and breast carcinoma.